-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stroke , commonly known as "stroke", it is the second largest cause of death, behind medsci.
Stroke , commonly known as "stroke", it is the second largest cause of death, behind medsci.
Prevention In 2018 alone, the number of deaths due to stroke in China was 1.
The early goal of reperfusion therapy for acute ischemic stroke is to restore blood flow in the ischemic but not yet infarcted brain area.
Clearly effective reperfusion treatment options include intravenous alteplase, intravenous tenecteplase, and mechanical thrombectomy.
Edaravone dexcamphanol is a compound preparation composed of two active ingredients.
Edaravone dexcamphanol is a compound preparation composed of two active ingredients.
The study is a multi-center, randomized, double-blind, comparative, phase III clinical trial.
The patients were randomly divided into two treatment groups at a ratio of 1:1: edaravone, dexcamphanol or edaravone injection was infused for 14 days.
The results showed that 585 people and 580 people were enrolled in the two groups.
Compared with the edaravone group, the edaravone dexcamphanol group had a significantly higher proportion of patients with a good functional outcome (mRankin≤1) on the 90th day of stroke (67.
In addition, in terms of side effects, including the incidence of adverse reactions (93.
In summary, the study shows that edaravone and dexcamphenol administered within 48 hours after an acute stroke can significantly improve the 90-day functional outcome, especially for female patients.
The administration of edaravone and dexcamphenol within 48 hours after acute stroke can significantly improve the 90-day functional outcome, especially for female patients.
references:
Xu J, et al.
TASTE Trial Investigators.
Leave a message here
